Proteasome inhibition and allogeneic hematopoietic stem cell transplantation: a review

Area of Science:

• Immunology
• Oncology
• Pharmacology

Background:

• The proteasome and ubiquitin system are key targets in cancer therapy, particularly for multiple myeloma.
• Proteasome inhibitors impact both cancer cells and immune cells, suggesting broader therapeutic potential.

Purpose of the Study:

• To review preclinical and clinical data on proteasome inhibition's effects on immunologic responses.
• To highlight the therapeutic applications of proteasome targeting in allogeneic hematopoietic stem cell transplantation (HSCT).

Main Methods:

• Review of existing scientific literature, including preclinical studies and clinical trials.
• Analysis of data on proteasome inhibitors' impact on immune cells and transplant outcomes.

Main Results:

• Proteasome inhibition influences non-neoplastic immune cells, indicating a role in immune modulation.
• Emerging data support the use of proteasome inhibitors in HSCT to manage graft-versus-host disease and enhance anti-leukemic effects.

Conclusions:

• Targeting the proteasome offers a strategy to modulate immune responses in the context of HSCT.
• Proteasome inhibition may improve the safety and efficacy of allogeneic HSCT for both toxicity management and disease control.